Valneva (VALN) Scheduled to Post Quarterly Earnings on Thursday

Valneva (NASDAQ:VALN) will issue its quarterly earnings data before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of ($0.30) per share for the quarter. Valneva has set its FY 2024 guidance at EPS.

Valneva (NASDAQ:VALN) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.02. Valneva had a negative return on equity of 20.01% and a negative net margin of 21.31%. The firm had revenue of $40.97 million for the quarter, compared to analyst estimates of $46.83 million.

Valneva Price Performance

Shares of VALN stock traded down $0.07 during midday trading on Tuesday, reaching $5.78. 15,267 shares of the company traded hands, compared to its average volume of 11,667. The firm has a market cap of $469.63 million, a PE ratio of -11.25 and a beta of 2.17. The company has a debt-to-equity ratio of 0.97, a current ratio of 2.63 and a quick ratio of 2.15. Valneva has a 1-year low of $5.40 and a 1-year high of $14.49. The firm’s 50 day simple moving average is $6.23 and its two-hundred day simple moving average is $7.18.

Analysts Set New Price Targets

Separately, HC Wainwright lowered their price objective on shares of Valneva from $23.00 to $20.00 and set a “buy” rating for the company in a research note on Friday, October 11th.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.